Drug | Jotup

Astrotech Introduces the “Gold Standard” of Mass Spectrometry into Narcotics Detection Market with its State-of-the-Art Tracer 1000

Retrieved on:

Monday, March 25, 2024

Astrotech, Conference, Heroin, Cocaine, ETD, Law enforcement, NTD, Prison, European Civil Aviation Conference, Airport, Mass spectrometry, ASTC, TRACER, Fentanyl, Drug

The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds.

Key Points:

The TRACER 1000 NTD is a high-performance laboratory instrument capable of rapid detection of trace levels of narcotic compounds in seconds.
Currently, the Company’s Tracer 1000 Explosive Trace Detector (ETD) is now found in multiple locations in 14 countries throughout the world.
The Astrotech Mass Spectrometer Technology™ (AMS Technology) drives the breakthrough TRACER 1000, as the first certified ETD to employ mass spectrometry as a trace detection security solution.
The TRACER 1000 is the only mass spectrometry-based ETD to have received European Civil Aviation Conference certification for both checkpoint and cargo security.

Village Farms International Applauds German Cannabis Progress

Retrieved on:

Friday, March 22, 2024

Patient, Certification, Cannabis, Growth, Legislation, Drug

VANCOUVER, British Columbia and ORLANDO, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- Village Farms International, Inc. (“Village Farms”) (NASDAQ: VFF) today applauded the passing of legislation partially legalizing cannabis for personal use in Germany, beginning April 1, 2024.

Key Points:

VANCOUVER, British Columbia and ORLANDO, Fla., March 22, 2024 (GLOBE NEWSWIRE) -- Village Farms International, Inc. (“Village Farms”) (NASDAQ: VFF) today applauded the passing of legislation partially legalizing cannabis for personal use in Germany, beginning April 1, 2024.
The new legislation will provide patients with greater access to high quality, legal products, which will be beneficial to further growth of the German medicinal cannabis market.
Village Farms has a strong link to the German market, having received our EU GMP certification from the District Government of Dusseldorf in 2022.
The German cannabis market is already core to Village Farms’ international cannabis strategy and, along with our participation in the Netherlands’ legal recreational cannabis program, central to our focus on legal cannabis opportunities in Europe,” said Michael DeGiglio, President and Chief Executive Officer, Village Farms.

HYTN Secures GMP Certification

Retrieved on:

Thursday, March 21, 2024

Certification, Growth, Therapeutic Goods Administration, Good manufacturing practice, Psilocybin, GMP, Cannabis, TGA, Drug

VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN "HYTN or The Company"), a Canadian company at the forefront of developing, formulating, and manufacturing products with psychoactive and psychotropic compounds, including those from cannabis and psilocybin, has been awarded Good Manufacturing Practice (GMP) certification by Australia's Therapeutic Goods Administration (TGA) for its Kelowna production facility.

Key Points:

VANCOUVER, British Columbia, March 21, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN "HYTN or The Company"), a Canadian company at the forefront of developing, formulating, and manufacturing products with psychoactive and psychotropic compounds, including those from cannabis and psilocybin, has been awarded Good Manufacturing Practice (GMP) certification by Australia's Therapeutic Goods Administration (TGA) for its Kelowna production facility.
Effective March 15th, 2024, this certification enables HYTN to manufacture cannabis dried flower into bulk and finished GMP medical products.
Although the company has previously serviced limited export opportunities, compliance with the PIC/S Guide to Good Manufacturing Practice for Medicinal Products through this new GMP certification now enables HYTN to engage in broader international trade.
It also coincides with the emergence of a brand new and sizable market in Germany, also requiring GMP certification for medicinal cannabis products.

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results

Retrieved on:

Thursday, March 21, 2024

NEW YORK and WALTHAM, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the fourth quarter and full year ending December 31, 2023, and provided an update on recent business achievements.

Key Points:

DNTH103 has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need.
Initial top-line results from this trial are anticipated to be available in the second half of 2025.
Dianthus successfully completed a private investment in public equity (“PIPE”) financing in January 2024 that resulted in gross proceeds of approximately $230 million.
Additional Information – For additional information on the Company’s financial results for the year ended December 31, 2023, please refer to the Form 10-K filed with the SEC.

Valneva to Present on its Chikungunya Vaccine IXCHIQ®, Participate in Multiple Events at the 24th World Vaccine Congress in Washington D.C.

Retrieved on:

Thursday, March 21, 2024

The Company will have a display in the exhibit area of the congress at booth #433.

Key Points:

The Company will have a display in the exhibit area of the congress at booth #433.
There will be two sessions, from 11:40 to 12:20 EST and again from 12:30 to 1:10pm EST.
Advisory Committee on Immunization Practices (ACIP)1 and these recommendations were adopted by the Centers for Disease Control and Prevention (CDC)2.
Additionally, Valneva CEO Thomas Lingelbach will present the Best Production / Process Development award at the event.

Verano Launches Cabbage Club™, Disrupting the Current Cannabis Retail Landscape with Industry-First National Membership Model

Retrieved on:

Wednesday, March 20, 2024

Reward, VIP, Zen, Patient, Status Quo, Club, Dime, Drug

CHICAGO, March 20, 2024 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced the launch of Cabbage Club™, a first-of-its-kind national cannabis membership club designed to reward and foster a community of loyal and passionate cannabis enthusiasts, customers and patients. Initially available in the Company’s 13 Zen Leaf™ dispensaries in New Jersey and Illinois, the Company plans to further expand Cabbage Club™ across its 13-state footprint, with the potential to scale additional benefits for members, including via third-party partnerships, in the future.

Key Points:

Membership expands on Dime and Quarter tiers by adding secret perks, only revealed to the very select few.
More information on Cabbage Club™ is available on cabbageclub.co , and fans can follow the Club on Instagram ( cabbageclub.co ), X ( Cabbageclub_co ) and Facebook ( Cabbage Club ).
For Cabbage Club media assets, please visit the following link: Cabbage Club Media Assets .
For additional Company media assets and information, please visit the Verano Company Newsroom .

Agrify Corporation Announces Turnkey Solventless Extraction Equipment Contract with Massachusetts-Based Company Blackstone Valley Cannabis

Retrieved on:

Wednesday, March 20, 2024

Rosin, Lab, Filtration, Freeze-drying, BVC, Drug

TROY, Mich., March 20, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced the signing of a Turnkey Solventless Extraction and Lab Equipment Package with Blackstone Valley Cannabis (“Blackstone Valley” or the “Customer”), a licensed vertical operator based in Uxbridge, MA.

Key Points:

TROY, Mich., March 20, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced the signing of a Turnkey Solventless Extraction and Lab Equipment Package with Blackstone Valley Cannabis (“Blackstone Valley” or the “Customer”), a licensed vertical operator based in Uxbridge, MA.
Blackstone Valley Cannabis has purchased Pure Pressure’s Turnkey Solventless Extraction and Lab Equipment Package, which includes an Axis Trichome Separator Hash Washing and Filtration package along with a Longs Peak Rosin Press with automated pressure control.
In addition, Blackstone Valley Cannabis has also elected Agrify’s 6-day on-site Advanced Solventless Training package, where Agrify’s Solventless Extraction Expert will train Blackstone Valley Cannabis’ team on Hash Washing, Freeze Drying, Pressing, Jar Tech, Mechanical Separation, and Vape Cart Formulation techniques.
Agrify’s Turnkey Solventless Extraction and Lab Equipment package will allow Blackstone Valley Cannabis to create some of the most unique solventless-based products that will be offered into the Massachusetts market.”
Justine Vota, Extraction Laboratory & Kitchen Manager at BVC said, “We at Blackstone Valley Cannabis are extremely excited to be utilizing Pure Pressure Solventless Extraction equipment for our Hash-washing and Rosin-pressing endeavors.

Vigil Neuroscience Appoints Petra Kaufmann, M.D., as Chief Medical Officer

Retrieved on:

Wednesday, March 20, 2024

Research, Employment, Plan, Novartis, Patient, Biostatistics, Microglia, Columbia University, University, Head, Senior, Drug, Therapy, Novartis Gene Therapies, Translational medicine, Bangladesh Technical Education Board, DSM-IV codes, Pharmaceutical industry

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer.

Key Points:

WATERTOWN, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced the appointment of Petra Kaufmann, M.D., M.S., F.A.A.N, as Chief Medical Officer.
"Dr. Kaufmann brings a wealth of experience that will be invaluable to the Vigil team,” said Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil.
“As we further the development of both iluzanebart and VG-3927, we will benefit from her extensive background in neurological and rare diseases, as well as her proven expertise in both domestic and global drug development.”
Dr. Kaufmann is an accomplished biotech executive joining Vigil Neuroscience from Affinia Therapeutics where she served as Chief Medical Officer leading medical, clinical, patient advocacy and regulatory strategy.
“I am honored and excited to join Vigil, a company at the forefront of developing innovative treatments for rare and common neurological diseases,” said Petra Kaufmann, M.D., M.S., F.A.A.N, Chief Medical Officer of Vigil.

Green Check Partners with Order.co to Enhance Access to Cost-Saving Solutions for the Cannabis Industry

Retrieved on:

Wednesday, March 20, 2024

GC, Growth, Partnership, Drug

"By enabling access to Order.co's innovative procurement platform through Green Check Connect, we're empowering cannabis businesses with essential tools to optimize their purchasing and payments processes," said Kevin Hart, CEO and founder of Green Check.

Key Points:

"By enabling access to Order.co's innovative procurement platform through Green Check Connect, we're empowering cannabis businesses with essential tools to optimize their purchasing and payments processes," said Kevin Hart, CEO and founder of Green Check.
"Together with Green Check, Order.co is poised to make a substantial difference in the operational efficiency and financial health of cannabis businesses.
"We are really excited to partner with Green Check and offer Order.co via Green Check Connect.
To learn more about Green Check and its industry-leading business and financial services marketplace, visit greencheckverified.com .

Media Advisory: Toronto & York Region Labour Council and Urban Alliance on Race Relations Mark International Day for the Elimination of Racial Discrimination

Retrieved on:

Tuesday, March 19, 2024

Racism, Elimination, International, Research, Policy, Racial discrimination, Metro Hall, Council, Town hall, Housing, Anti-racism, UARR, Drug

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- On March 21st, the Toronto & York Region Labor Council (TYRLC) and the Urban Alliance on Race Relations (UARR) will mark the International Day for the Elimination of Racial Discrimination (IDERD) by presenting Mayor Olivia Chow and Toronto City Councillors with practical and impactful policy proposals, tools and solutions to address racial inequity in Toronto.

Key Points:

TORONTO, March 19, 2024 (GLOBE NEWSWIRE) -- On March 21st, the Toronto & York Region Labor Council (TYRLC) and the Urban Alliance on Race Relations (UARR) will mark the International Day for the Elimination of Racial Discrimination (IDERD) by presenting Mayor Olivia Chow and Toronto City Councillors with practical and impactful policy proposals, tools and solutions to address racial inequity in Toronto.
At discussion will be how racial inequity manifests in Toronto around housing, transit, community services, policing, and good jobs.
The Toronto & York Region Labour Council represents over 220,000 workers from diverse sectors across the Toronto region.
The Urban Alliance on Race Relations works with the community, public and private sectors to provide educational programs and research critical to addressing racism in our society.